

Address: 2500 NW, 79th Avenue, Suite 200, Miami, FL 33122.

Date Revoked: August 26, 2010.

Reason: Failed to maintain a valid bond.

**Sandra L. Kusumoto,**

Director, Bureau of Certification and Licensing.

[FR Doc. 2010-23679 Filed 9-21-10; 8:45 am]

BILLING CODE 6730-01-P

## FEDERAL MARITIME COMMISSION

### Rescission of Order of Revocation

Notice is hereby given that the Order revoking the following license is being rescinded by the Federal Maritime Commission pursuant to section 19 of the Shipping Act of 1984 (46 U.S.C. Chapter 409) and the regulations of the Commission pertaining to the licensing of Ocean Transportation Intermediaries, 46 CFR Part 515.

License Number: 004063F.

Name: VIP Transport, Inc.

Address: 2703 Wardlow Road, Corona, CA 91720.

Order Published: FR: 9/1/2010 (Volume 75, No. 169, Pg. 53697).

**Sandra L. Kusumoto,**

Director, Bureau of Certification and Licensing.

[FR Doc. 2010-23675 Filed 9-21-10; 8:45 am]

BILLING CODE 6730-01-P

## FEDERAL MARITIME COMMISSION

### Ocean Transportation Intermediary License Applicants

Notice is hereby given that the following applicants have filed with the Federal Maritime Commission an application for a license as a Non-Vessel-Operating Common Carrier (NVO) and/or Ocean Freight Forwarder (OFF)—Ocean Transportation Intermediary (OTI) pursuant to section 19 of the Shipping Act of 1984 as amended (46 U.S.C. Chapter 409 and 46 CFR 515). Notice is also hereby given of the filing of applications to amend an existing OTI license or the Qualifying Individual (QI) for a license.

Interested persons may contact the Office of Transportation Intermediaries, Federal Maritime Commission, Washington, DC 20573.

Allright Shipping, Inc. (NVO & OFF), 1350 Bronx River Avenue, Bronx, NY 10472. *Officer:* Denzil Barker, President, (Qualifying Individual). Application Type: New NVO & OFF License.

Cambria Global Logistics, LLC (OFF), 12140 Quilting Lane, Boca Raton, FL

33428. *Officers:* Panu Virtanen, Managing Member, (Qualifying Individual). Kathleen Virtanen, Managing Member. Application Type: New OFF License.

Glory Express Inc. (NVO), 19825 Hamilton Avenue, Torrance, CA 90502. *Officer:* JinYoung Bae, President/Secretary/CFO, (Qualifying Individual). Application Type: QI Change.

K&K Express, LLC dba K2 Logistics (NVO & OFF), 2980 Commers Drive, #100, Eagan, MN 55121. *Officers:* Wanda L. Dessent, Vice President-International-Houston, (Qualifying Individual). Christiaan Walhof, CEO/President/CFO. Application Type: QI Change.

Overseas Cargo, Inc. (NVO & OFF), 9614 Pondwood Road, Boca Raton, FL 33428. *Officer:* Suramya (A.K.A. Ron) T. Atapattu, President/Secretary/Treasurer/Director, (Qualifying Individual). Application Type: New NVO & OFF License.

Smile Cha dba SMH Global Transport (NVO), 8636 York Circle, La Palma, CA 90623. *Officer:* Smile Cha, Sole Proprietor, (Qualifying Individual). Application Type: New NVO License.

Westwind Shipping and Logistics, Inc. (NVO), 38 West 32nd Street, Suite 1309B, New York, NY 10001. *Officer:* Harry Taurani, President/Secretary/Treasurer/CFO, (Qualifying Individual). Application Type: New NVO License.

World Class Solutions LLC (NVO & OFF), 3901 NW 79th Avenue, Suite 230, Doral, FL 33166. *Officer:* Jorgelina G. Marsaglia, President, (Qualifying Individual). Application Type: New NVO & OFF License.

Dated: September 17, 2010.

**Karen V. Gregory,**

Secretary.

[FR Doc. 2010-23676 Filed 9-21-10; 8:45 am]

BILLING CODE 6730-01-P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

[Docket No. FDA-2010-N-0465]

#### Agency Information Collection Activities; Proposed Collection; Comment Request; Experimental Study: Effect of Promotional Offers in Direct-to-Consumer Prescription Drug Print Advertisements on Consumer Product Perceptions

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing an opportunity for public comment on the proposed collection of certain information by the agency. Under the Paperwork Reduction Act of 1995 (the PRA), Federal agencies are required to publish notice in the **Federal Register** concerning each proposed collection of information and to allow 60 days for public comment in response to the notice. This notice solicits comments on the Experimental Study: Effect of Promotional Offers in Direct-to-Consumer Prescription Drug Print Advertisements on Consumer Product Perceptions. This study is designed to investigate the impact of the presence of coupons offering purchase incentives such as free-trial offers, discounts, and money-back guarantees on consumers' perceptions of product risks and benefits in direct-to-consumer (DTC) print ads.<sup>1</sup> Notice of proposed information collection for this project was previously published in the **Federal Register** of December 15, 2008 (73 FR 76034). This notice is being republished due to significant revisions in the burden and study design.

**DATES:** Submit either electronic or written comments on the collection of information by November 22, 2010.

**ADDRESSES:** Submit electronic comments on the collection of information to <http://www.regulations.gov>. Submit written comments on the collection of information to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. All comments should be identified with the docket number found in brackets in the heading of this document.

**FOR FURTHER INFORMATION CONTACT:**

Elizabeth Berbakos, Office of Information Management, Food and Drug Administration, 1350 Piccard Dr., PI50-400B, Rockville, MD 20850, 301-796-3792, [Elizabeth.Berbakos@fda.hhs.gov](mailto:Elizabeth.Berbakos@fda.hhs.gov).

**SUPPLEMENTARY INFORMATION:** Under the PRA (44 U.S.C. 3501-3520), Federal agencies must obtain approval from the

<sup>1</sup> While the Federal Food, Drug and Cosmetic Act (the FD&C Act) provides FDA with authority to regulate prescription drug advertisements that are false or misleading, the FD&C Act does not provide FDA with the authority to regulate the pricing of prescription drugs. Thus, FDA is merely interested in studying the effects, if any, of the presence of various promotional offers in DTC advertisements on consumers' perceptions of product risks and benefits, and recognizes that it does not actually regulate the dollar or other incentive amount of coupons, price incentives, or rebate offers with respect to how they affect the price of prescription drugs or biological products.